◀ Back to MAPK1
MAP2K1 — MAPK1
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAP2K1 Activity, MAPK1 Activity)
Schmidt et al., J Biol Chem 2000*
Evidence: To elucidate the role of MAPKs in keratinocyte differentiation, activation of ERK, JNK, and p38 in response to stimulation with extracellular calcium was analyzed. We provide evidence that calcium-induced differentiation of keratinocytes is associated with rapid and transient activation of the Raf/MEK/ERK pathway. Stimulation of keratinocytes with extracellular calcium resulted in activation of Raf isozymes and their downstream effector ERK within 10-15 min, but did not increase JNK or p38 activ...
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAP2K1 Activity, MAPK1 Activity)
Evidence: Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAP2K1 Activity, MAPK1 Activity)
Zhou et al., J Biol Chem 2002*
Evidence: The dual phosphorylation of Thr-183 and Tyr-185 in ERK2 is catalyzed by MAPK/ERK kinase 1 (MEK1).
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAP2K1 Activity, MAPK1 Activity)
Yeung et al., Nature 1999*
Evidence: Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK)
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAP2K1 Activity, MAPK1 Activity)
Forcet et al., Nature 2002
Evidence: in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAPK1 Activity)
Evidence: 9166761;11971971;15935618
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K1
(directlyIncreases, MAPK1 Activity)
Zhou et al., J Biol Chem 2002*
Evidence: The dual phosphorylation of Thr-183 and Tyr-185 in ERK2 is catalyzed by MAPK/ERK kinase 1 (MEK1).
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK2 (MAP2K2)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
RAF1
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK2 (MAPK1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
ERK2 (MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
dynamin gtpase (DNM1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
dynamin gtpase (DNM1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, activates)
-
BioCarta mapkinase signaling pathway:
MEK1/MEK2 (MAP2K2/MAP2K1)
→
ERK1/ERK2 (MAPK3/MAPK1)
(modification, activates)
-
KEGG Oocyte meiosis:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Vascular smooth muscle contraction:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Dorso-ventral axis formation:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG VEGF signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Focal adhesion:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Gap junction:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Toll-like receptor signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Natural killer cell mediated cytotoxicity:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG T cell receptor signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG B cell receptor signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Fc epsilon RI signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Fc gamma R-mediated phagocytosis:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Long-term potentiation:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Neurotrophin signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Cholinergic synapse:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Long-term depression:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Regulation of actin cytoskeleton:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Insulin signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG GnRH signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Progesterone-mediated oocyte maturation:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG MAPK signaling pathway:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Melanogenesis:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Prion diseases:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Influenza A:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Pathways in cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Colorectal cancer:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Renal cell carcinoma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Pancreatic cancer:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Endometrial cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Glioma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Glioma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3/PIK3CA/PIK3CB/PIK3CD/PIK3CG
(protein-protein, activation)
-
KEGG Prostate cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Thyroid cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Thyroid cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Melanoma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Bladder cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Chronic myeloid leukemia:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Acute myeloid leukemia:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Non-small cell lung cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG ErbB signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Chemokine signaling pathway:
MAP2K1
→
MAPK1/MAPK3
(protein-protein, activation)
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2-active (MAPK3/MAPK1)
→
MEK1/MEK2 complex (MAP2K1-MAP2K2)
(modification, activates)
Catalanotti et al., Nature structural & molecular biology 2009, Brunet et al., FEBS Lett 1994*
Evidence: assay
-
NCI Pathway Database Trk receptor signaling mediated by the MAPK pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
York et al., Nature 1998*
Evidence: mutant phenotype, reporter gene, other species
-
NCI Pathway Database PDGFR-beta signaling pathway:
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-MAP2K1_MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
McKay et al., Proc Natl Acad Sci U S A 2009
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2-active (MAPK3/MAPK1)
→
KSR/14-3-3 (dimer)/MEK1-2 complex (KSR1-MAP2K1_MAP2K2)
(modification, activates)
McKay et al., Proc Natl Acad Sci U S A 2009
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database mTOR signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Roux et al., Proc Natl Acad Sci U S A 2004, Ma et al., Cell 2005
-
NCI Pathway Database mTOR signaling pathway:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Roux et al., Proc Natl Acad Sci U S A 2004, Ma et al., Cell 2005
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB-MAP2K1_MAP2K2)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB-MAP2K1_MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Bernatchez et al., Br J Pharmacol 2001
Evidence: genetic interaction
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Bernatchez et al., Br J Pharmacol 2001
Evidence: genetic interaction
-
NCI Pathway Database CXCR3-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Bonacchi et al., J Biol Chem 2001, Smit et al., Blood 2003
Evidence: assay
-
NCI Pathway Database CXCR3-mediated signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Bonacchi et al., J Biol Chem 2001, Smit et al., Blood 2003
Evidence: assay
-
NCI Pathway Database Netrin-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Forcet et al., Nature 2002, Hérincs et al., J Cell Sci 2005
Evidence: genetic interaction, mutant phenotype
-
NCI Pathway Database Netrin-mediated signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Forcet et al., Nature 2002, Hérincs et al., J Cell Sci 2005
Evidence: genetic interaction, mutant phenotype
-
NCI Pathway Database IL2-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2 (MAP2K1/MAP2K2)
(modification, collaborate)
Perkins et al., J Exp Med 1993*
Evidence: mutant phenotype, other species
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1/MEK2 complex (MAP2K1-MAP2K2)
(modification, collaborate)
Catalanotti et al., Nature structural & molecular biology 2009
Evidence: assay
-
NCI Pathway Database ErbB1 downstream signaling:
MEK1/MEK2 complex (MAP2K1-MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Catalanotti et al., Nature structural & molecular biology 2009
Evidence: assay
-
NCI Pathway Database Ras signaling in the CD4+ TCR pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
Crews et al., Proc Natl Acad Sci U S A 1992*
Evidence: assay, other species
-
NCI Pathway Database BCR signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
-
NCI Pathway Database ErbB2/ErbB3 signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Monje et al., J Biol Chem 2008, Vijapurkar et al., J Biol Chem 1998
Evidence: assay
-
NCI Pathway Database ErbB2/ErbB3 signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Monje et al., J Biol Chem 2008, Vijapurkar et al., J Biol Chem 1998
Evidence: assay
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
Glading et al., J Biol Chem 2001*, Howe et al., Cell 1992, Roy et al., Mol Cell Biol 2005, Ren et al., Proc Natl Acad Sci U S A 2007, Minden et al., Science 1994, Zheng et al., J Biol Chem 1993, Huang et al., Proc Natl Acad Sci U S A 1993
Evidence: assay, physical interaction
-
NCI Pathway Database EPHB forward signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
Vindis et al., J Cell Biol 2003
Evidence: mutant phenotype
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
Xu et al., J Biol Chem 1999*, Howe et al., Cell 1992, McKay et al., Proc Natl Acad Sci U S A 2009, Minden et al., Science 1994, Zheng et al., J Biol Chem 1993, Huang et al., Proc Natl Acad Sci U S A 1993
Evidence: assay, physical interaction
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2 (MAP2K1/MAP2K2)
(modification, collaborate)
Crews et al., Proc Natl Acad Sci U S A 1992*
Evidence: assay, other species
-
NCI Pathway Database IFN-gamma pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
Hu et al., J Biol Chem 2001, Roy et al., Proc Natl Acad Sci U S A 2002
Evidence: mutant phenotype
-
NCI Pathway Database GMCSF-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Guthridge et al., Blood 2004, Lanfrancone et al., Oncogene 1995, Sato et al., EMBO J 1993, Itoh et al., Mol Cell Biol 1998*, Jenkins et al., Blood 1998*
Evidence: genetic interaction
-
NCI Pathway Database GMCSF-mediated signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Guthridge et al., Blood 2004, Lanfrancone et al., Oncogene 1995, Sato et al., EMBO J 1993, Itoh et al., Mol Cell Biol 1998*, Jenkins et al., Blood 1998*
Evidence: genetic interaction
-
NCI Pathway Database Endothelins:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Yogi et al., Arterioscler Thromb Vasc Biol 2007
-
NCI Pathway Database Endothelins:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Yogi et al., Arterioscler Thromb Vasc Biol 2007
-
NCI Pathway Database Nongenotropic Androgen signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Unni et al., Cancer Res 2004, Cheng et al., Endocrinology 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database Nongenotropic Androgen signaling:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Unni et al., Cancer Res 2004, Cheng et al., Endocrinology 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Karihaloo et al., J Biol Chem 2001*, Paumelle et al., Oncogene 2002
Evidence: assay
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Karihaloo et al., J Biol Chem 2001*, Paumelle et al., Oncogene 2002
Evidence: assay
-
Reactome Reaction:
MAPK1
→
MAP2K1
(reaction)
Yang et al., J Biol Chem 2003*, Xiong et al., J Biol Chem 2003*, Preger et al., Proc Natl Acad Sci U S A 2004*, Torii et al., Dev Cell 2004*, Ziv et al., J Biol Chem 2006*, Zheng et al., J Biol Chem 1993*
-
WikiPathways ESC Pluripotency Pathways:
MAP2K1/MAP2K3/SEPP1/MAP2K5/MAP2K6/MAP2K2
→
MAPK7/MAPK1/MAPK6/MAPK4/MAPK12
(activation)
-
WikiPathways Endothelin Pathways:
MAP2K1
→
MAPK1
(mim-stimulation)
-
WikiPathways ErbB Signaling Pathway:
MAP2K1
→
MAPK1
(activation)
-
WikiPathways Focal Adhesion:
SEPP1/MAP2K5/MAP2K6/MAP2K2/MAP2K3/MAP2K1
→
MAPK4/MAPK7/MAPK12/MAPK1/MAPK6
(activation)
-
WikiPathways Human Thyroid Stimulating Hormone (TSH) signaling pathway:
MAP2K1
→
MAPK1
(activation)
-
WikiPathways MAPK Cascade:
MAP2K1/MAP2K2
→
MAPK3/MAPK1
(activation)
-
WikiPathways MicroRNAs in cardiomyocyte hypertrophy:
MAP2K1/MAP2K2
→
MAPK3/MAPK1
(activation)
-
WikiPathways Osteopontin Signaling:
MAP2K1
→
MAPK3/MAPK1
(activation)
-
WikiPathways PDGF Pathway:
MAP2K1
→
MAPK1/MAPK3
(mim-stimulation)
-
WikiPathways Regulation of Actin Cytoskeleton:
MAP2K1/MAP2K2
→
MAPK1/MAPK3/MAPK4/MAPK6
(activation)
-
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling:
MAP2K1
→
MAPK1
(mim-necessary-stimulation)
Venkatasubbarao et al., Cancer Res 2005*, Ravanti et al., J Biol Chem 1999*
-
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling:
MAP2K1
→
MAPK1
(mim-necessary-stimulation)
Venkatasubbarao et al., Cancer Res 2005*, Ravanti et al., J Biol Chem 1999*
-
WikiPathways Signaling Pathways in Glioblastoma:
MAP2K1/MAP2K2/MAP2K3/MAP2K4/MAP2K5/MAP2K6/MAP2K7
→
MAPK1/MAPK3
(mim-stimulation)
-
WikiPathways Signaling of Hepatocyte Growth Factor Receptor:
MAP2K2/MAP2K1
→
MAPK1/MAPK3
(activation)
-
WikiPathways Structural Pathway of Interleukin 1 (IL-1):
MAP2K1
→
MAPK3/MAPK1
(activation)
-
WikiPathways 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression:
Complex of MAP2K2-MAP2K1
→
Complex of MAPK1-MAPK3
(activation)
-
WikiPathways Association Between Physico-Chemical Features and Toxicity Associated Pathways:
MAP2K1
→
MAPK1
(activation)
-
WikiPathways BDNF-TrkB Signaling:
MAP2K1
→
MAPK1
(activation)
-
WikiPathways Bladder Cancer:
MAP2K1
→
MAPK1
(activation)
-
WikiPathways Cardiac Hypertrophic Response:
MAP2K2/MAP2K1
→
MAPK3/MAPK1
(activation)
-
WikiPathways Chemokine signaling pathway:
MAP2K1
→
MAPK1/MAPK3
(activation)
-
WikiPathways Common Pathways Underlying Drug Addiction:
MAP2K1/MAP2K2
→
MAPK3/MAPK1
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Bind Interaction:
MAP2K1
—
MAPK1
Bardwell et al., J Biol Chem 2001*
-
IRef Bind_translation Interaction:
MAP2K1
—
MAPK1
(affinity chromatography technology)
Bardwell et al., J Biol Chem 2001*
-
IRef Bind_translation Interaction:
MAP2K1
—
MAPK1
(experimental interaction detection)
Bardwell et al., J Biol Chem 2001*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, pull down)
Yeung et al., Mol Cell Biol 2000*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, pull down)
Wunderlich et al., J Cell Biol 2001*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, enzymatic study)
Xu Be et al., J Biol Chem 2001*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(physical association, affinity chromatography technology)
Xu Be et al., J Biol Chem 2001*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, enzymatic study)
Chen et al., J Biol Chem 2001*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, protein complementation assay)
Srivastav et al., Biochem J 2011
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(physical association, affinity chromatography technology)
Kubota et al., Nat Cell Biol 2011*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, pull down)
Ho et al., J Biol Chem 2003
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(physical association, affinity chromatography technology)
Sanz-Moreno et al., Mol Cell Biol 2003*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, enzymatic study)
Sanz-Moreno et al., Mol Cell Biol 2003*
-
IRef Biogrid Interaction:
MAP2K1
—
MAPK1
(direct interaction, two hybrid)
Robinson et al., J Biol Chem 2002*
-
IRef Dip Interaction:
Complex of BLVRA-MAPK1-MAP2K1
(anti bait coimmunoprecipitation)
Lerner-Marmarosh et al., Proc Natl Acad Sci U S A 2008*
-
IRef Hprd Interaction:
MAP2K1
—
MAPK1
(two hybrid)
Bardwell et al., J Biol Chem 2001*, Xu Be et al., J Biol Chem 2001*, Robinson et al., J Biol Chem 2002*, Robinson et al., J Biol Chem 2002*, Eblen et al., J Biol Chem 2003*, Alessi et al., EMBO J 1994*
-
IRef Hprd Interaction:
MAP2K1
—
MAPK1
(in vivo)
Bardwell et al., J Biol Chem 2001*, Xu Be et al., J Biol Chem 2001*, Robinson et al., J Biol Chem 2002*, Robinson et al., J Biol Chem 2002*, Eblen et al., J Biol Chem 2003*, Alessi et al., EMBO J 1994*
-
IRef Hprd Interaction:
MAP2K1
—
MAPK1
(in vitro)
Bardwell et al., J Biol Chem 2001*, Xu Be et al., J Biol Chem 2001*, Robinson et al., J Biol Chem 2002*, Robinson et al., J Biol Chem 2002*, Eblen et al., J Biol Chem 2003*, Alessi et al., EMBO J 1994*
-
IRef Hprd Interaction:
Complex of 51 proteins
(in vivo)
Luttrell et al., Proc Natl Acad Sci U S A 2001
-
IRef Hprd Interaction:
Complex of 17 proteins
(in vivo)
Stewart et al., Mol Cell Biol 1999
-
IRef Intact Interaction:
MAP2K1
—
MAPK1
(physical association, anti bait coimmunoprecipitation)
Casar et al., EMBO J 2007*
-
IRef Intact Interaction:
MAP2K1
—
MAPK1
(phosphorylation reaction, protein kinase assay)
Villeneuve et al., EMBO J 2013*
-
IRef Ophid Interaction:
MAP2K1
—
MAPK1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
-
IRef Ophid Interaction:
MAP2K1
—
MAPK1
(aggregation, confirmational text mining)
Xu Be et al., J Biol Chem 2001*
Text-mined interactions from Literome
Castoria et al., EMBO J 1999
(Breast Neoplasms) :
Furthermore, the selective
MEK 1 inhibitor, PD 98059,
inhibits oestradiol and progestin stimulation of
Erk-2 and the steroid dependent S-phase entry
Hashimoto et al., Life Sci 1999
:
To this end, we examined changes in cellular morphology and MAPK activation in NE-stimulated BEC monolayer, and the effect of PD 98059 as the specific inhibitor for MAPK kinase-1 (
MEK-1 , the upstream
regulator of
MAPK ) on NE-induced changes in cellular morphology and MAPK activation
Gire et al., Oncogene 1999
:
Conversely, selective
activation of
MAPK by a constitutively-active
MAPKK1 mutant failed to mimic the action of Ras and, although this was achievable with activated Raf, micro-injection of anti-ras antibodies showed that this still required endogenous wild-type Ras function
Martel-Pelletier et al., Arthritis Rheum 1999
(Osteoarthritis) :
Within minutes, IL-17 induced the phosphorylation of
mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 ) ... Within minutes, IL-17 induced the phosphorylation of mitogen activated protein kinase kinase-1/2 (
MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
McDuffie et al., J Cardiovasc Pharmacol 2000
:
The agonist stimulated phosphorylation of
MAPK was
blocked by the 5-HT1b-receptor antagonist isamoltane ( 0.01-10 p3M ) and the
MEK-1 inhibitor PD 098059 ( [ 2- ( 2'-amino-3'-methoxy-phenyl ) -oxanaphthalen-4-one ] ; 0.01-10 microM¿
Pluskota et al., Eur J Biochem 2000
(MAP Kinase Signaling System) :
The
MEK-1 inhibitor PD 98059
blocked ERK-1/2 phosphorylation, and treatment of endothelial cells with PD 98059 resulted in apoptosis even upon Fg : ICAM-1 ligation
Newton et al., Br J Pharmacol 2000
:
We have therefore used these cells to examine the effect of the selective
mitogen activated protein ( MAP ) kinase inhibitors ; PD098059, a mitogen activated and extracellular regulated kinase kinase (
MEK) 1 inhibitor , UO126, a dual MEK1 & MEK2 inhibitor, and SB203580, a p38 MAP kinase inhibitor in the IL-1beta dependent release of PGE ( 2 )
Learish et al., Brain Res Dev Brain Res 2000
:
These data provide evidence that
activation of
MAPK by
MEK1 is important for the proliferation of NP cells
Hayashi et al., Eur Respir J 2000
:
Lung fibroblasts were stimulated with BK in the presence or in the absence of PD98059, a specific
MAPK/ERK kinase-1 inhibitor, or SB203580, a specific p38
MAPK inhibitor , and IL-6 or IL-8 production and their gene expression was examined
Hayashi et al., Hepatology 2000
:
Moreover, the
MAPK/ERK activation by HCV core protein was blocked in the
presence of the specific
MEK1 inhibitor, PD98059
Kim et al., IUBMB Life 2000
:
S1P treatment transiently activated
Erk-1/-2 in a dose dependent manner, and its activation was
blocked by pertussis toxin, expression of RasN17, or inhibition of Raf or
MEK-1/-2
Tu et al., J Biomed Sci 2001
(Carcinoma, Hepatocellular) :
On the other hand, PD98059, a specific inhibitor of
mitogen activated protein kinase kinase ,
blocks TPA induced
MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Choi et al., Cancer Res 2001
(Glioblastoma...) :
Herein, we demonstrate that : ( a ) stimulation with agonistic anti-Fas monoclonal antibody CH-11 and human recombinant soluble Fas ligand induces expression of the CC chemokine MCP-1 and the CXC chemokine interleukin-8 by human glioma cell lines at the mRNA and protein levels in a dose- and time dependent manner ; ( b ) selective pharmacological inhibitors of
MEK1 ( U0126 and PD98059 ) and p38 mitogen activated protein kinase ( MAPK ) ( SB202190 ) suppress Fas mediated chemokine expression in a dose dependent manner ; ( c ) Fas ligation on human glioma cells
leads to activation of both extracellular signal regulated kinases ERK1/ERK2 and p38
MAPK ; and ( d ) GBM samples express higher levels of Fas compared with normal control brain, which correlates with increased interleukin 8 expression
Tseng et al., Biochem Biophys Res Commun 2001
:
To determine the involvement of MEK1-p42/p44 MAPK pathway in mediating DAB2 gene expression, we have performed the following experiments and found that ( i ) there was sustained activation of p42/p44
MAPK , but not p38 MAPK, upon K562 cells differentiation ; ( ii ) application of MEK1 inhibitor U0126 reduced the expression of DAB2 protein, mRNA and promoter activity, as well as cell differentiation ; ( iii ) constitutively active
MEK1 increased DAB2 promoter activity ; and ( iv ) dominant negative ERK2 abolished constitutively active MEK1 induced DAB2 promoter activity
Iwata et al., J Biol Chem 2001
(MAP Kinase Signaling System) :
Transfection of constitutively active
MEK-1 resulted in
MAPK phosphorylation in alpha-synuclein expressing cells and improved cell viability even under reduced serum conditions
Boyd et al., Neuropharmacology 2002
:
Using two structurally distinct inhibitors of the
activation of
MEK1 (
mitogen activated protein ( MAP) kinase kinase 1 ), PD 98059 and U 0126, we have shown that the MAP kinase signalling cascade does not appear to underlie muscarinic inhibition of IK ( SO ), recorded using whole-cell patch-clamp methods
Braz et al., J Cell Biol 2002
(Cardiomyopathy, Hypertrophic) :
A mechanism whereby PKC alpha might regulate hypertrophy was suggested by the observations that wild-type PKC alpha induced
extracellular signal regulated kinase1/2 ( ERK1/2 ), that dominant negative PKC alpha inhibited PMA induced ERK1/2 activation, and that dominant negative
MEK1 ( up-stream of ERK1/2 )
inhibited wild-type PKC alpha induced hypertrophic growth
Tao et al., Biochem J 2002
:
We present data showing that overexpression of the serine threonine kinase,
mitogen activated protein kinase/extracellular-signal regulated kinase kinase kinase-1 ( MEKK1 ), but not nuclear factor-kappa B inducing kinase, or
MAP kinase/ERK kinase-1 (MEK1) , can significantly increase the level of CD28RE/AP1-driven luciferase ( Luc ) reporter gene expression in Jurkat E6-1 cells
McKinstry et al., Cancer Biol Ther 2002
(Breast Neoplasms...) :
Inhibition of
MEK1/2 caused modest reductions in basal
MAPK activity and transiently suppressed UCN-01 stimulated MAPK activity below that of MEK1/2 inhibitor alone
Huang et al., Biochem Biophys Res Commun 2003
:
MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a
mitogen activated protein kinase kinase ( MAP2K ), which in turn
activates a
mitogen activated protein kinase ( MAPK )
Waas et al., Biochemistry 2003
:
To do this,
ERK2 was quantitatively
activated by
MAPKK1 in vitro by monitoring the stoichiometry and site specificity of phosphorylation using a combination of protein mass spectrometry, tryptic peptide analysis, and ( 32 ) P radiolabeling
Yu et al., Oncogene 2004
(Leukemia) :
These events were accompanied by the caspase independent downregulation of Raf-1, inactivation of
MEK1/2 , ERK, Akt, p70S6K, dephosphorylation of GSK-3, and
activation of c-Jun-N-terminal kinase (JNK) and p38
MAPK
Sananbenesi et al., J Neurosci 2003
(MAP Kinase Signaling System) :
Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 ( aSvg-30 ) prevented stress enhanced fear conditioning and
Mek-1/2 dependent
activation of
Erk-1/2 and p90Rsk-1
Yue et al., Curr Biol 2004
:
The MAPK activator
MEK1 is
required for mitotic activation of p42
MAPK in Xenopus egg extracts ; however, the identity of the kinase that activates MEK1 is unknown
Keeton et al., Biochim Biophys Acta 2004
(Carcinoma, Hepatocellular...) :
Inhibition of
MEK1 significantly
inhibited extracellularly regulated kinase
(ERK)1/2 activation and insulin regulated Gene33 transcription and protein levels in H4IIE cells
de Bernardo et al., J Neurochem 2004
:
MEK-1/2 and lipoxygenase (LOX) inhibitors, as well as ascorbic acid,
prevent ERK-1/2 activation and neuronal loss, but the inhibition of nitric oxide sintase (NOS), cyclo-oxygenase (COX), c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein kinase ( p38 MAPK ) does not have protective effects
Zhang et al., Arterioscler Thromb Vasc Biol 2005
(Vasculitis) :
In contrast,
mitogen activated protein kinase kinase-1 (
MEK1 )
inhibition ( dominant negative MEK1 adenovirus or inhibitor U0126 ) suppressed Ang II-induced NF-kappaB promoter activity, NF-kappaB DNA binding activity, p65 phosphorylation, and led to 70 % reduction in IL-6 transcription/production
Minelli et al., Peptides 2006
:
It greatly
enhances the phosphorylation of hsp27, alpha-B-crystallin, Cdc2, and p-38
MAPK , whereas it decreases the phosphorylation of
MEK1 , Cav 2, GSK3a, PKB/Akt, PKCdelta, PKCgamma, and Erk2
Mukherjee et al., Carcinogenesis 2006
(Chromosomal Instability) :
Activation of both ERKs and p38
MAPK by BPDE and attenuation of BPDE induced p53 accumulation by U0126 or SB202190, specific inhibitor of
MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation
Lee et al., J Cell Physiol 2006
:
TNF-alpha enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44
MAPK , p38, and JNK were significantly
attenuated by inhibitors of
MEK1/2 ( U0126 ), p38 ( SB202190 ), and JNK ( SP600125 )
Chien et al., Biochem Biophys Res Commun 2006
(Lung Neoplasms) :
SB203580, a p38
MAPK inhibitor, but not PD098059 and SP600125, specific
inhibitor of
MKK1 and selective inhibitor of JNK, respectively, suppressed COX-2 expression
Hu et al., J Biol Chem 2006
:
Conversely, overexpression of constitutively activated
Mek1 induced
Erk-1/2 phosphorylation and MMP-9 expression
Giannopoulou et al., American journal of physiology. Renal physiology 2006
(Fibrosis...) :
Constitutive
activation of
Erk-1/2 by ectopic expression of activated
Mek1 mimicked IFN-gamma and suppressed TGF-beta(1) mediated alpha-SMA expression
Wu et al., Cell Microbiol 2006
(MAP Kinase Signaling System) :
Our results showed that phosphorylated mitogen activated protein kinase ( MAPK ) kinase ( MEK) 1/2, p44/p42
MAPK and p90 ribosomal S6 kinase (p90RSK) were observed and this pathway was
inhibited by
MEK1/2 inhibitors U0126 and PD98059
Klegeris et al., FASEB J 2006
(Astrocytoma...) :
It is also
attenuated by PD 98059, an inhibitor of the MAPK/extracellular regulated kinase kinase
MEK1/2 , SP 600125, an inhibitor of c-Jun N-terminal kinase (JNK), and SB 202190, an inhibitor of p38
MAPK
Bajpai et al., Invest Ophthalmol Vis Sci 2007
(Anoxia...) :
Inhibition of
MEK1 by pharmacologic and dominant negative mutant approaches
attenuated 15 ( S ) -HETE induced phosphorylation of ERK1/2 and JNK1 but not p38
MAPK
Park et al., Mol Cancer Ther 2008
(Carcinoma, Hepatocellular...) :
Inhibition of p38
MAPK or knockdown of BID, FAS associated death domain, or CD95 expression
suppressed MEK1/2 inhibitor and 17AAG lethality
Aroor et al., Alcohol 2009
:
These results suggest that Ang II-mediated accumulation of phospho-p42/44
MAPK in the hepatocyte nucleus
involves MEK 1/2 dependent activation and this effect is potentiated by ethanol
Liu et al., PloS one 2010
:
Expression of constitutively active
MKK1 also
attenuated rapamycin inhibition of IGF-1 stimulated phosphorylation of
Erk1/2 and cell motility
Tartaglia et al., Molecular syndromology 2010
:
SHP2 ( encoded by PTPN11 ), SOS1, BRAF, RAF1 and
MEK1 positively
contribute to
RAS-MAPK signaling, and possess complex autoinhibitory mechanisms that are impaired by mutations
Malarkannan et al., J Immunol 2012
:
This includes actin polymerization, tubulin multimerization, microtubule organizing center formation, calcium/calmodulin signaling,
Pak/Raf/Mek1/2 mediated
Erk1/2 activation , formation of maestrosome, E-cadherin, and CD44 mediated signaling and glycogen synthase kinase-3/adenomatous polyposis coli mediated ß-catenin activation
Pike et al., Cell Signal 2013
:
Truncated
MEK1 is
required for transient activation of
MAPK signalling in G2 phase cells
Winston et al., J Biol Chem 1995
:
Preferential
involvement of
MEK1 in the tumor necrosis factor-alpha induced activation of
p42mapk/erk2 in mouse macrophages
Huwiler et al., Br J Pharmacol 1994
:
2. Both nucleotides stimulate phosphorylation and
activation of
mitogen activated protein kinase and a biphasic phosphorylation of the up-stream
mitogen activated protein kinase kinase
Gardner et al., Mol Biol Cell 1994
:
Raf and
MAPK/extracellular signal regulated kinase kinase ( MEKK ) independently phosphorylate and
activate MEK-1
Gardner et al., J Biol Chem 1996
:
Pharmacological inhibition of
MEK-1 activity by incubation of cells with the compound PD 098059
blocked p42(MAPK) activation and FGF-2 protection against apoptosis
Genot et al., EMBO J 1996
:
Constitutively active
MAPKK-1 fully
activates ERK-2 and the transcription factor Elk-1, but does not substitute for activated p21ras and synergize with calcium/calcineurin signals to induce NFAT
Mansour et al., Biochemistry 1996
:
Both the acidic substitutions and the N-terminal deletion increase Vmax, V/K ( m ),
ERK2 , and V/K ( m ), ATP, as is also
observed following phosphorylation of wild-type
MKK1
Ho et al., J Neurochem 1997
:
Mobility shift, phosphoepitope analysis, and direct measurement of kinase activity indicated that the
Mek1 inhibitor dose-dependently
blocked basal and okadaic acid induced
MAPK activation
Rose et al., J Immunol 1997
:
The selective MAPK/extracellular signal regulated kinase-1 (
MEK-1 ) inhibitor PD 098059
inhibited activation of
p42MAPK induced by Fc gamma R cross linking, but not p38 or JNK/SAPK activation
Bazan et al., Curr Eye Res 1997
:
Corneal tissue expresses ERK2 or MAPK, and both
MEK1 and MEK2, the immediate upstream
regulators of
MAPK
Nantel et al., J Biol Chem 1998
:
Interaction of Grb10 with Raf1 is constitutive, while interaction between Grb10 and
MEK1 needs insulin treatment of the cells and
follows mitogen activated protein kinase activation
Daum et al., FEBS Lett 1998
:
Pervanadate inhibits
mitogen activated protein kinase kinase-1 in a
p38MAPK dependent manner
Denis-Henriot et al., Endocrinology 1998
:
Wild-type Galpha12 overexpression prevented the decrease in
MAPK activity and
induced MEK1 , but not B-Raf, expression
Tsatsanis et al., Oncogene 1998
(Lymphoma, T-Cell) :
Since the activation of NFAT is MAPK dependent these findings suggested that the activation of
MAPK by Tpl-2 is either independent or only partially
dependent on
MEK1 and MEK2